[0] Investrend Research Announces Investment Opinion.Business Editors NOTE TO EDITORS: The following is an investment opinion issued by Investrend Research NEW YORK--(BUSINESS WIRE)--April 11, 2001
Investrend Research issued its Quarterly Update Report today on
Vasogen Inc. (AMEX/TSE: MEW/VAS), maintaining a BUY recommendation.
Analyst Randall D. Lewis, CFA reviews Vasogen's unique
position focused on bringing to market its immune modulation
therapy, a platform technology to treat cardiovascular,
autoimmune, and related inflammatory diseases. This report,
and all of our prior research reports on Vasogen Inc., is
available at no charge at www.investrend.com/.
Analyst coverage for Vasogen Inc. (AMEX AMEX See: American Stock Exchange : MEW mew, miaow the vocal sound characteristic of domestic cats; in various languages it is spelled in 31 different ways, which include 'miaow', 'meow', 'myaus', 'mio', and 'mau'. See also vocalization. ) continues by Investrend Research with an Update Quarterly Report with the analyst maintaining a buy recommendation. The company's immune modulation therapy currently targets the following primary medical categories: 1) the treatment of cardiovascular diseases, including peripheral vascular disease Peripheral Vascular Disease Definition Peripheral vascular disease is a narrowing of blood vessels that restricts blood flow. It mostly occurs in the legs, but is sometimes seen in the arms. (PVD PVD abbr. peripheral vascular disease PVD Peripheral vascular disease, see there ) and congestive heart failure congestive heart failure, inability of the heart to expel sufficient blood to keep pace with the metabolic demands of the body. In the healthy individual the heart can tolerate large increases of workload for a considerable length of time. (CHF CHF In currencies, this is the abbreviation for the Swiss Franc. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. ); 2) the protection of vital organs and tissues against Ischemia/Reperfusion (I/R) Injury during major vascular surgery; 3) the treatment of autoimmune diseases; and 4) the treatment of chronic lymphocytic leukemia chronic lymphocytic leukemia n. Abbr. CLL Lymphocytic leukemia occurring mainly in older adults, characterized by slow onset and gradual progression of symptoms. . The company is also developing its cell processing technology, currently being targeted towards the prevention of Graft-versus-Host Disease (GvHD) in leukemia patients, a common complication of bone marrow transplants. The company has a comprehensive intellectual property portfolio, holding eight U.S. patents and over 25 patent applications pending throughout the world. Mr. Lewis concludes on Vasogen, "We are looking for this to be a possible breakout year for the company and are staying with our previous revenue and earnings estimates. The company's first revenue recognition will likely come in the form of upfront and/or milestone payments -- or payments received from potential strategic partners. We feel these payments (estimated to be between $5-20 million) are likely to occur in this fiscal year, but in the interest of conservative timing, we are going at the lower end of this bound and maintaining our FY 2001 revenue estimate at approximately $12 million. The company continues to be well capitalized... and Vasogen represents a solid investment opportunity at these price levels for this type of investment and risks." Mr. Lewis has more than ten years experience in security and portfolio analysis, and served as an equity analyst at SSI Investment Management, Inc., financial analyst for Griffin Financial Services, and research and market analyst for Eneric Financial Services. He has published several articles, most recently HFR Journal of Hedge Fund Research, on merger arbitrage. He has a BA degree with honors in finance from California State University, Fullerton California State University, Fullerton, commonly known as CSUF, CSU Fullerton, or Cal State Fullerton, is a part of the California State University system. The University is located in the city of Fullerton, California, in northern Orange County. , an MBA from the Anderson School at UCLA, and is a Chartered Financial Analyst Chartered Financial Analyst (CFA) An experienced financial analyst who has passed examinations in economics, financial accounting, portfolio management, security analysis, and standards of conduct given by the Institute of Chartered Financial Analysts. (CFA (Computer Fraud and Abuse Act of 1986) Signed into law in 1986, the CFA was a significant step forward in criminalizing unauthorized access to computer systems and networks. The Act applies to "federal interest computers" that include any system used by the U.S. ). Public Analysis & Review (PAR) is a program of Investrend Research. PAR reports are performed on behalf of the public, and are not a service to any company. PAR analysts are responsible only to the public. PAR analysts are paid in advance to eliminate pecuniary interests and insure independence. PAR enrollment fees are $19,700 per annum. Please read disclaimers on the Investrend website (www.investrend.com) before investing. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion